icddr,b in collaboration with Dhaka North City Corporation (DNCC) and Expanded Program on Immunization (EPI) of Bangladesh commenced a typhoid conjugate vaccine effectiveness study.
The study will be conducted among 43,350 children of the age group of nine-month to under-16 years in the city’s Mirpur area, said an icddr,b press release on Sunday, reports UNB.
The study is a part of the Typhoid Vaccine Acceleration Consortium (TyVAC) project, in which researchers are conducting studies to evaluate how much typhoid can be prevented by the typhoid conjugate vaccine in Bangladesh.
Globally, about one hundred and fifty thousand patients die due to typhoid every year while the disease also causes severe illness to many others.
Speaking about the outcome of the study, Dr Firdausi Qadri, principal investigator of the study who also leads the Infectious Diseases Division at icddr,b, said, “The study will help us generate evidence about the safety profile of the vaccine and lead to impact assessment and determination of the effectiveness of the vaccine in preventing typhoid fever, hospitalizations as well as to generate immunization programme.”
Other collaborating institutes include; University of Oxford, UK, University of Maryland, USA, and PATH and the study is supported by the Bill and Melinda Gates Foundation.